STVN

Business Context and Reporting Period

Company: Stevanato Group S.p.A.
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: A global provider of drug containment, drug delivery, and diagnostic solutions, as well as engineering equipment for the pharmaceutical and biotechnology industries. The Group operates two segments: Biopharmaceutical and Diagnostic Solutions and Engineering.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 7.8% (Q2) and 7.3% (H1) year-over-year, driven primarily by the Biopharmaceutical and Diagnostic Solutions segment. High-value solutions (syringes, EZ-fill vials) grew 16.4% in Q2 and 16.5% in H1.
• Profitability Decline: Net profit decreased 22.7% in Q2 and 9.3% in H1 compared to the prior year. This was primarily due to a EUR 12.2 million loss on the sale of the subsidiary Balda C. Brewer Inc. and an increase in the effective tax rate.
• Effective Tax Rate: The effective tax rate rose to 39.8% (Q2) and 34.1% (H1) from 24.1% and 24.3% respectively. This increase is attributed to the expiration of the Italian "IRES premiale" tax regime and the non-deductibility of the loss on the Balda C. Brewer sale.
• Segment Performance: The Engineering segment saw revenue decline (2.0% in Q2, 16.4% in H1) but improved gross margins (12.0% in Q2, 13.6% in H1) due to optimization plans and a better project mix.
• Cash Flow: Operating cash flow decreased significantly (29% in Q2, 26% in H1) due to higher working capital absorption, specifically increases in inventories and contract assets.

Guidance, Outlook, and Risks

• Capacity Expansion: The Group is ramping up new facilities in Fishers, Indiana (U.S.) and Latina, Italy. Commercial production has begun, with full capacity expected to be reached over time. Temporary inefficiencies and higher depreciation during ramp-up are currently tempering margins.
• Divestiture: The sale of Balda C. Brewer Inc. was completed on June 30, 2026, to optimize the industrial footprint. Proceeds are expected to be collected in future periods.
• Tariff and Regulatory Risks: The Group faces uncertainty regarding U.S. import tariffs. While some refunds were received for duties paid under the IEEPA (following a Supreme Court decision), future recovery of paid duties is not guaranteed. The Group expects to absorb some costs but is working to pass others to customers.
• Internal Controls: The Company disclosed that its internal controls over financial reporting were not effective as of December 31, 2025, due to material weaknesses. Remediation plans are underway, including enhanced period-end controls and IT general controls.
• Market Risks: Significant exposure to foreign currency exchange rates (USD, CNY, MXN) and commodity prices (natural gas, electricity). The Group utilizes hedging instruments to mitigate these risks.

Investor Verification Checklist

• Loss on Sale: Verify the final consideration received for Balda C. Brewer Inc. and the timing of cash inflows, as the receivable was outstanding at period-end.
• Tax Position: Confirm the sustainability of the higher effective tax rate in 2026 following the loss of the Italian tax incentive regime.
• Ramp-up Costs: Monitor the timeline for the new U.S. and Italian facilities to reach target productivity and the associated impact on gross margins.
• Internal Controls: Review progress on the remediation of material weaknesses in internal controls over financial reporting.
• Tariff Recovery: Assess the success of ongoing efforts to recover previously paid U.S. import duties and the potential impact of future trade policies.
• Working Capital: Track the normalization of inventory and contract asset levels, which currently represent a significant cash outflow.